Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma

Marc Sorigue, Juan Manuel Sancho, Alberto Pineda, Olga Garcia, David Lopez, Miriam Moreno, Gustavo Tapia, Montse Batlle, Christelle Ferra, Susanna Vives, Gladys Ibarra, Evarist Feliu, Josep Maria Ribera

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Abstract

© 2017 Elsevier Ltd Nephrotoxicity is a well-known side effect of platinum-based chemotherapy. We retrospectively assessed the incidence and prognostic impact of nephrotoxicity with ESHAP rescue chemotherapy in 74 lymphoma patients (61 aggressive lymphomas). A higher incidence of nephrotoxicity (estimated glomerular filtration rate <60 mL/min) was found when ESHAP was administred on an outpatient vs. inpatient basis (14/39 vs. 4/35). Patients submitted to ASCT with renal failure had a lower overall survival (OS) than those with normal renal function (2-yr OS probability [95%CI]: 88% [77%–99%] vs. 50% [22%–78%]). Outpatient administration of ESHAP may not be optimal for all patients and the impact of ESHAP-induced renal failure on ASCT outcomes in lymphoma needs to be assessed in prospective studies.
Original languageEnglish
Pages (from-to)98-101
JournalLeukemia Research
Volume58
DOIs
Publication statusPublished - 1 Jul 2017

Keywords

  • Autologous stem cell transplantation
  • ESHAP
  • Lymphoma
  • Nephrotoxicity
  • Platinum
  • Survival

Fingerprint Dive into the research topics of 'Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma'. Together they form a unique fingerprint.

Cite this